Page 64 Manual de Interações medicamentosas no tratamento da dor crónica

May T, R. B. (2007). Serum concentrations of pregabalin in patients with epilepsy: The influence of dose,
age, and comedication. Ther Drug Monit , 29, 789-794.
McLachlan, A., Bath, S., Naganathan, V., & al., e. (2011). Clinical pharmacology of analgesic medicines
in older people: impact of frailty and cognitive impairment. British Journal of Clinical Pharmacology , 71
(3), 351-364.
Mozayani, A., & Raymon, L. (2004). Handbook of Drug Interactions. A Clinical and Forensic Guide. New
Jersey: Humana Press.
Nieuwstraten C, L. N. (2006). Systematic Overview of Drug Interactions with Antidepressant Medications
. Can J Psychiatry , 51, 300-316.
Overholser, B., & Foster, D. (2011). Opioid pharmacokinetic Drug-Drug Interactions. The American Jour-
nal of Managed Care , 17 (11), S276-S287.
Pergolizzi, J. (2011). Quantifying the Impact of Drug-Drug Interactions Associated With Opioids . Am J
Manag Care , 17, S288-S292.
Pergolizzi, J., Boger, R., & Budd, K. (2008). Opioids and Management of Chronic Severe Pain in the
Elderly: Concensus Statement of an International Expert Panel with Focus on the six most often used
World Health Organization Step II Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Mor-
phine, Oxycodone). Pain Practice , 8 (4), 287-313.
Riechelmann, R., Moreira, F., Smaletz, O., & Saad, E. (2005). Potential for drug interactions in hospitali-
zed cancer patients. Cancer Chemother Pharmacol , 56, 286-290.
Riechelmann, R., Tannock, I., & Wang, L. (2007). Potential drug interactions and duplicate prescriptions
among cancer patients. J Natl Cancer Inst , 99, 592-600.
Riechelmann, R., Zimmermann, C., & Chin, S. (2008). Potential drug interactions in cancer patients re-
cieving supportive care exclusively. J Pain Symptom Manage , 35, 535-543.
Sadhasivam, S., & Chidambaran, V. (2012). Pharmacogenomics of opioids and perioperative pain mana-
gement . Pharmacogenomics , 13 (15), 1719-1740.
Scripture, C., & Figg, W. (2006). Drug Interactions in cancer therapy. Nature Reviews Cancer , 6, 546-
558.
Shannon, M. (2007). Drug Interactions. In M. Shannon, S. Borron, & M. Burns, Haddad an Winchester's
Clinical Management of Poisoning and Drug Overdose (pp. 97-104). Philadelphia: Saunders/Elsevier.
Smith, H. (2009). Opioid Metabolism. Mayo Clin Proc. , 84 (7), 613-624.
Strevel, E., Ing, D., & Siu, L. (2007). Molecularly Targeted Oncology Therapeutics and Prolongation of the
QT Interval. JOURNAL OF CLINICAL ONCOLOGY , 25 (22), 3362-3371.
Tascilar, M., Jong, F., Verweij, J., & Mathijssen, R. (2006). Complementary and Alternative Medicine
During Cancer Treatment: Beyond Innocence . The Oncologist , 11, 732741-.
Turner E, L. J. (2006). Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryp-
tophan. Pharmacology & Therapeutics , 109, 325-338.
Van Leeuwen, R., Brundel, D., & Neef, C. (2013). Prevalence of potencial drug-drug interactions in can-
cer patients treated with oral anticancer drugs. Br J Cancer , 108, 1071-1078.
Van Leeuwen, R., Swart, E., & Boven, E. (2011). Potential drug interactions in cancer therapy: a preva-
lence study using an advanced screening method. Ann Oncol , 22, 2334-2341.
Weingart, S., Bach, P., Johnson, S., Langbaum, T., Muller, R., O´Brien, S., et al. (2008). NCCN Task
Force Report: Oral Chemotherapy. Journal of the National Comprehensive Cancer Network , 6 (suppl3),
S1-S14.
Wynn G, O. J. (2003). Drug Interaction principles for medical practice. Washington: American Psychiatric
Publishing.

64